Wednesday, April 17, 2019 7:51:56 PM
Let's do the Math For ELTP Shall We
850 Million Shares Outstanding.
Let's call it 1 Billion Shares Outstanding for Simplicity.
Each $10 Million in profit is $.01 earnings per share.
Now assign a multiple or a PE. Current PE averages for companies are between 20--25
BUT
High Growth Companies get High PE's
ELTP will be a High Growth Company.
$10 Million in Profit.
Each $.01 in earning X PE 30, 60 = $.30 or $.60
$30 Million in Profit or $.03 X PE 30, 60 = $.90 or $1.80.
Isradipine is a $500 Million Market if it Works.
Think Isradipine can product profit of $30 Million or more for ELTP? I do.
Now the above example applies to the $4 Billion in Generic Drugs ELTP has entered.
My Conclusion --- Massive Gains Next two years and into the future with or without Isradipine.
Isradipine is Elite's FREE WILDCARD!!
Another CLUE: It Would NOT be Unreasonable for ELTP
to Get a Very High PE in Anticipation of Fast High Growth.
100+ PE Can Happen.
850 Million Shares Outstanding.
Let's call it 1 Billion Shares Outstanding for Simplicity.
Each $10 Million in profit is $.01 earnings per share.
Now assign a multiple or a PE. Current PE averages for companies are between 20--25
BUT
High Growth Companies get High PE's
ELTP will be a High Growth Company.
$10 Million in Profit.
Each $.01 in earning X PE 30, 60 = $.30 or $.60
$30 Million in Profit or $.03 X PE 30, 60 = $.90 or $1.80.
Isradipine is a $500 Million Market if it Works.
Think Isradipine can product profit of $30 Million or more for ELTP? I do.
Now the above example applies to the $4 Billion in Generic Drugs ELTP has entered.
My Conclusion --- Massive Gains Next two years and into the future with or without Isradipine.
Isradipine is Elite's FREE WILDCARD!!
Another CLUE: It Would NOT be Unreasonable for ELTP
to Get a Very High PE in Anticipation of Fast High Growth.
100+ PE Can Happen.
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
